Coronary angiography is essential for patients admitted with non-ST-elevation acute coronary syndrome, since it allows physicians to confirm the diagnosis, stratify the risk, and define the revascularization and antithrombotic management strategies. There is no doubt that these patients should be studied invasively, but the timing for that is still uncertain. Coronary catheterization within<a href="https://solaci.org/en/2017/10/09/early-coronary-angiography-in-high-risk-non-st-elevation-acs/" title="Read more" >...</a>
With Absorb Out, New Resorbable Scaffolds Have Come onto the Market
By restoring vascular physiology and eliminating the inflammatory focus and the chance of fracture and neo atherosclerosis inherent to DES, bioresorbable scaffolds offer the potential to improve long term outcomes. A number of bioresorbable materials have been tested, mainly polylactic acid, with several limitations that have taken the Absorb bioresorbable scaffold out of the market.<a href="https://solaci.org/en/2017/10/09/with-absorb-out-new-resorbable-scaffolds-have-come-onto-the-market/" title="Read more" >...</a>
Frequency and Evolution of Cardiac Perforation in Patients with a History of MRS
Courtesy of Dr. Carlos Fava. Coronary perforation (CP) is a very uncommon event (≈0.4%), associated with severe complications that entail risk of death. It has usually been related to patients with a history of myocardial revascularization surgery (MRS). However, this group usually presents lower rates of cardiac tamponade due to pericardial fibrosis caused by surgery. This<a href="https://solaci.org/en/2017/10/05/frequency-and-evolution-of-cardiac-perforation-in-patients-with-a-history-of-mrs/" title="Read more" >...</a>
New Strategies for the Femoropopliteal Artery
Courtesy of Dr. Carlos Fava. The incidence of peripheral vascular disease is clearly increasing, progressing towards critical ischemic claudication and amputation. Angioplasty is currently the treatment of choice for these pathologies. Several times, an implanted stent ends up cracking due to extensive calcification, increasing the rate of restenosis and worsening critical ischemia. Technological development on drug-eluting<a href="https://solaci.org/en/2017/10/04/new-strategies-for-the-femoropopliteal-artery/" title="Read more" >...</a>
These Are the Thrombosis Predictors for Absorb Bioresorbable Scaffolds
J Am Coll Cardiol Intv has recently published a special issue on bioresorbable scaffolds. Abbott’s decision to pull Absorb off the market probably prompted the fast publishing of all related articles sent to the journal. Bioresorbable scaffolds were developed in hopes that they would reduce the rates of events per year 1 year post-implantation by 1.5%-3%<a href="https://solaci.org/en/2017/09/28/these-are-the-thrombosis-predictors-for-absorb-bioresorbable-scaffolds/" title="Read more" >...</a>
Very Late Thrombosis in Bioresorbable Scaffolds
The presence of a metallic device interrupts normal laminar flow and creates an artery environment that favors thrombosis, leaving the vessel vulnerable to very late thrombosis. Dual antiplatelet therapy, a better implantation technique, and several improvements in new drug-eluting stents (DES) (thinner struts, and higher polymer stability and biocompatibility) have lowered significantly the incidence of<a href="https://solaci.org/en/2017/09/26/very-late-thrombosis-in-bioresorbable-scaffolds/" title="Read more" >...</a>
Additional Benefit from Radial Artery Graft in Myocardial Revascularization Surgery
Used to different extents according to institution, surgeon, and historical time, the radial artery graft is yet to prove whether it can improve the outcomes of myocardial revascularization surgery when added to a single or bilateral internal thoracic artery graft. The ART (Arterial Revascularization Trial) was designed to compare survival after bilateral vs. single left internal<a href="https://solaci.org/en/2017/09/21/additional-benefit-from-radial-artery-graft-in-myocardial-revascularization-surgery/" title="Read more" >...</a>
FOURIER: Efficacy of Evolocumab for Ultra-Low LDL Levels
It seems that a LDL level of 70 mg/dL is no longer low enough for high-risk secondary patients; in consequence, this study attempted to set a new target, one that appears almost impossible to reach: 40 mg/dL or lower. This study, simultaneously presented at the European Society of Cardiology Congress 2017 and published in The Lancet, showed<a href="https://solaci.org/en/2017/09/13/fourier-efficacy-of-evolocumab-for-ultra-low-ldl-levels/" title="Read more" >...</a>
Minimum Appropriate Follow-Up Reduces Mortality After Endoprosthesis Implantation
No study has been able to prove long-term benefit of regular imaging follow-up after abdominal aortic aneurysm repair by means of endoprosthesis implantation. This is important because the costs for these studies are high, which should be added to potential radiation and contrast morbidity. This work sought to characterize the association between post-endovascular abdominal aortic aneurysm<a href="https://solaci.org/en/2017/09/08/minimum-appropriate-follow-up-reduces-mortality-after-endoprosthesis-implantation/" title="Read more" >...</a>
Polymer-Free DES Also Show Efficacy in Anticoagulated Patients with High Risk for Bleeding
Patients who receive chronic anticoagulation therapy and then undergo angioplasty are frequently discharged on a triple anti-thrombotic scheme that usually includes aspirin, clopidogrel, and warfarin. The optimal duration of this indication remains unclear, particularly for patients at high bleeding risk. According to expert consensus, patients receiving chronic anticoagulation may receive from 1 to 12 months of dual<a href="https://solaci.org/en/2017/09/08/polymer-free-des-also-show-efficacy-in-anticoagulated-patients-with-high-risk-for-bleeding/" title="Read more" >...</a>